Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs

BACKGROUND: Day‐to‐day variability impacts safety of insulin therapy and the choice of monitoring strategies. Side‐by‐side comparisons of insulin formulations in diabetic dogs are scarce. HYPOTHESIS/OBJECTIVES: Insulin glargine 300 U/mL (IGla300) and insulin degludec (IDeg) are associated with less...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Michelle, Pires, Jully, Crakes, Katti, Greathouse, Rachel, Quach, Nina, Gilor, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478047/
https://www.ncbi.nlm.nih.gov/pubmed/34241910
http://dx.doi.org/10.1111/jvim.16178
_version_ 1784575974057181184
author Miller, Michelle
Pires, Jully
Crakes, Katti
Greathouse, Rachel
Quach, Nina
Gilor, Chen
author_facet Miller, Michelle
Pires, Jully
Crakes, Katti
Greathouse, Rachel
Quach, Nina
Gilor, Chen
author_sort Miller, Michelle
collection PubMed
description BACKGROUND: Day‐to‐day variability impacts safety of insulin therapy and the choice of monitoring strategies. Side‐by‐side comparisons of insulin formulations in diabetic dogs are scarce. HYPOTHESIS/OBJECTIVES: Insulin glargine 300 U/mL (IGla300) and insulin degludec (IDeg) are associated with less day‐to‐day glucose variability compared to porcine lente (PL) in diabetic dogs. ANIMALS: Seven intact male purpose‐bred beagles with toxin‐induced diabetes. METHODS: In this repeated measured study, PL, IGla300 and IDeg were compared in 2 phases: once‐daily (q24h) and twice‐daily (q12h) administration. Interstitial glucose concentrations (IG) were measured continuously throughout the study. For each formulation, maximal q24h dose was determined using the same algorithm (while avoiding hypoglycemia) and then maintained for 72 hours. In phase 2, 70% of the maximal q24h dose was administered q12h and maintained for 5 days regardless of hypoglycemia. Coefficient of variation (CV) and glycemic variability percentage (GVP) were calculated to determine day‐to‐day and intraday variability, respectively. RESULTS: There was no difference in day‐to‐day variability between PL, IGla300, and IDeg in the q24h phase. In the q12h phase, day‐to‐day variability was higher (P = .01) for PL (CV = 42.6 ± 6.8%) compared to IGla300 and IDeg (CV = 30.1 ± 7.7%, 25.2 ± 7.0%, respectively). The GVP of PL was lower (P = .02) compared to IGla300. There was no difference between PL, IGla300 and IDeg in %time IG < 70 mg/dL. CONCLUSIONS AND CLINICAL IMPORTANCE: Insulin degludec and IGla300 administered q12h were associated with lower day‐to‐day variability, which might be advantageous in minimizing monitoring requirements without increasing the risk of hypoglycemia.
format Online
Article
Text
id pubmed-8478047
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-84780472021-10-01 Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs Miller, Michelle Pires, Jully Crakes, Katti Greathouse, Rachel Quach, Nina Gilor, Chen J Vet Intern Med SMALL ANIMAL BACKGROUND: Day‐to‐day variability impacts safety of insulin therapy and the choice of monitoring strategies. Side‐by‐side comparisons of insulin formulations in diabetic dogs are scarce. HYPOTHESIS/OBJECTIVES: Insulin glargine 300 U/mL (IGla300) and insulin degludec (IDeg) are associated with less day‐to‐day glucose variability compared to porcine lente (PL) in diabetic dogs. ANIMALS: Seven intact male purpose‐bred beagles with toxin‐induced diabetes. METHODS: In this repeated measured study, PL, IGla300 and IDeg were compared in 2 phases: once‐daily (q24h) and twice‐daily (q12h) administration. Interstitial glucose concentrations (IG) were measured continuously throughout the study. For each formulation, maximal q24h dose was determined using the same algorithm (while avoiding hypoglycemia) and then maintained for 72 hours. In phase 2, 70% of the maximal q24h dose was administered q12h and maintained for 5 days regardless of hypoglycemia. Coefficient of variation (CV) and glycemic variability percentage (GVP) were calculated to determine day‐to‐day and intraday variability, respectively. RESULTS: There was no difference in day‐to‐day variability between PL, IGla300, and IDeg in the q24h phase. In the q12h phase, day‐to‐day variability was higher (P = .01) for PL (CV = 42.6 ± 6.8%) compared to IGla300 and IDeg (CV = 30.1 ± 7.7%, 25.2 ± 7.0%, respectively). The GVP of PL was lower (P = .02) compared to IGla300. There was no difference between PL, IGla300 and IDeg in %time IG < 70 mg/dL. CONCLUSIONS AND CLINICAL IMPORTANCE: Insulin degludec and IGla300 administered q12h were associated with lower day‐to‐day variability, which might be advantageous in minimizing monitoring requirements without increasing the risk of hypoglycemia. John Wiley & Sons, Inc. 2021-07-09 2021 /pmc/articles/PMC8478047/ /pubmed/34241910 http://dx.doi.org/10.1111/jvim.16178 Text en © 2021 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC. on behalf of the American College of Veterinary Internal Medicine. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle SMALL ANIMAL
Miller, Michelle
Pires, Jully
Crakes, Katti
Greathouse, Rachel
Quach, Nina
Gilor, Chen
Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
title Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
title_full Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
title_fullStr Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
title_full_unstemmed Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
title_short Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
title_sort day‐to‐day variability of porcine lente, insulin glargine 300 u/ml and insulin degludec in diabetic dogs
topic SMALL ANIMAL
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478047/
https://www.ncbi.nlm.nih.gov/pubmed/34241910
http://dx.doi.org/10.1111/jvim.16178
work_keys_str_mv AT millermichelle daytodayvariabilityofporcinelenteinsulinglargine300umlandinsulindegludecindiabeticdogs
AT piresjully daytodayvariabilityofporcinelenteinsulinglargine300umlandinsulindegludecindiabeticdogs
AT crakeskatti daytodayvariabilityofporcinelenteinsulinglargine300umlandinsulindegludecindiabeticdogs
AT greathouserachel daytodayvariabilityofporcinelenteinsulinglargine300umlandinsulindegludecindiabeticdogs
AT quachnina daytodayvariabilityofporcinelenteinsulinglargine300umlandinsulindegludecindiabeticdogs
AT gilorchen daytodayvariabilityofporcinelenteinsulinglargine300umlandinsulindegludecindiabeticdogs